Dr. Ikechukwu I. Akunyili
Claim this profileEphrata Cancer Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
9 drugs studied
Area of expertise
1Lung Cancer
Stage IV
MET positive
KRAS positive
2Non-Small Cell Lung Cancer
Stage IV
MET positive
KRAS positive
Affiliated Hospitals
Clinical Trials Ikechukwu I. Akunyili is currently running
Amivantamab
for Non-Small Cell Lung Cancer
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Recruiting1 award Phase 216 criteria
Tepotinib + Ramucirumab
for Lung Cancer
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 24 criteria
More about Ikechukwu I. Akunyili
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ikechukwu I. Akunyili has experience with
- Ramucirumab
- Biospecimen Collection
- Data Collection
- Quality-of-Life Assessment
- Questionnaire Administration
- Chemotherapy
Breakdown of trials Ikechukwu I. Akunyili has run
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ikechukwu I. Akunyili specialize in?
Ikechukwu I. Akunyili focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are MET positive.
Is Ikechukwu I. Akunyili currently recruiting for clinical trials?
Yes, Ikechukwu I. Akunyili is currently recruiting for 2 clinical trials in Ephrata Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Ikechukwu I. Akunyili has studied deeply?
Yes, Ikechukwu I. Akunyili has studied treatments such as Ramucirumab, Biospecimen Collection, Data Collection.
What is the best way to schedule an appointment with Ikechukwu I. Akunyili?
Apply for one of the trials that Ikechukwu I. Akunyili is conducting.
What is the office address of Ikechukwu I. Akunyili?
The office of Ikechukwu I. Akunyili is located at: Ephrata Cancer Center, Ephrata, Pennsylvania 17522 United States. This is the address for their practice at the Ephrata Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.